Krystal Biotech Inc. (KRYS) experienced a significant pre-market surge of 5.25% on Monday, driven by the release of robust first-quarter financial results and a recent positive regulatory development for its oncology pipeline.

The company announced its Q1 2026 financial and operating results pre-market, reporting product revenue of USD 116.357 million and net income of USD 55.932 million. These strong figures indicate healthy commercial execution and profitability, providing a fundamental catalyst for the stock's upward movement.

Additionally, investor sentiment was bolstered by news that the U.S. FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to KB707, Krystal Biotech's redosable HSV-based immunotherapy for advanced or metastatic non-small cell lung cancer. This regulatory status, announced prior to the earnings, provides the drug candidate with enhanced FDA guidance and potential for accelerated review, elevating the profile of the company's emerging oncology franchise.